Results 211 to 220 of about 68,932 (348)

POLY (ADP-RIBOSE) POLYMERASE (PARP-1) EXPRESSION IN MALIGNANT MELANOMAS FROM PHOTO EXPOSED AREAS OF THE HEAD AND NECK REGION

open access: yes, 2003
Cutaneous malignant melanoma (CMM) incidence rate and related deaths are increasing faster than most of other skin malignancies with an incidence which has tripled during the last 40 years and continues to grow.
LO MUZIO, LORENZO   +12 more
core  

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel   +27 more
wiley   +1 more source

Cutaneous Malignant Melanoma in Chile: Differences in Tumor Thickness and Overall Survival Between Patients From Public and Private Health Care Centers. [PDF]

open access: yesDermatol Pract Concept, 2023
Martínez G   +8 more
europepmc   +1 more source

Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma

open access: yesJournal of the European Academy of Dermatology and Venereology, 2013
E. Emri   +9 more
semanticscholar   +1 more source

HPV125‐induced generalized verrucosis

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven Niklas Burmann   +7 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

Sex differences in rising trends of cutaneous malignant melanoma in Norway, 1954–2008

open access: yesMelanoma research, 2013
T. Robsahm   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy